Overview: Alkaline Phosphatase Isoenzymes (ALP Isoenzymes) Panel
Introduction: The Alkaline Phosphatase Isoenzymes Panel assesses ALP isoenzyme levels using serum samples. In India, elevated ALP is common in liver/bone disorders linked to metabolic syndrome (prevalence rising with diabetes/obesity ~20-30%), NAFLD, vitamin D deficiency, and bone diseases. Presents with jaundice, bone pain, fatigue, severe complications if untreated. Per clinical chemistry practices (aligned ICMR guidelines), test uses spectrophotometry for analysis over 1-2 days with high sensitivity/specificity, valuable for enzyme source evaluation in elevated total ALP cases. Targets individuals with metabolic/liver/bone issues, addressing origin identification for treatment. With elevated morbidity from underdiagnosis in metabolic syndrome patients, supports public health efforts for precise management, reduced complications. Serum-based approach ensures reliable assessment.
Other Names: ALP Iso Pnl.
FDA Status: FDA approved, CLIA certified for clinical chemistry, compliant with 2025 standards.
Historical Milestone: Introduced 1970sâ€"1980s with fractionation; in India, prominence with rising metabolic syndrome.
Purpose: Screens for 5 parameters including total ALP to guide liver/bone disorder assessment, determine source, inform treatment/prevention in metabolic contexts.
Test Parameters: 1. Total ALP, 2. Liver ALP, 3. Bone ALP, 4. Intestinal ALP, 5. Placental ALP.
Pretest Condition: Fasting 10-12 hours; report jaundice, bone pain, fatigue, symptoms.
Specimen: 3 mL serum in 1 SST, transported promptly.
Sample Stability at Room Temperature: 8 hours proper handling to preserve integrity.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, short-term storage preferred.
Sample Stability at Frozen: 6 months at -20 degrees Celsius, long-term storage.
Medical History: Details on jaundice, bone pain, pregnancy, liver/bone history, medications affecting ALP.
Consent: Written consent detailing purpose, risks untreated liver/bone disorders, benefits early detection, minimal discomfort.
Procedural Considerations: Processing using spectrophotometry by trained personnel, sterile technique, avoid hemolysis, interpret 1-2 days with controls. Labs controlled, quality assurance, kit storage per specs.
Factors Affecting Result Accuracy: Delays, improper storage, hemolysis, recent meal affect results. Clinical correlation/additional testing recommended.
Clinical Significance: Abnormal patterns indicate liver/bone source, further investigation/specialist. Normal distribution follow-up if total ALP elevated.
Specialist Consultation: GPs/hepatology/endocrinology/gastroenterology for management, coordination.
Additional Supporting Tests: Liver function panel, bone markers, imaging confirmation.
Test Limitations: Overlap in patterns/interference from other sources; comprehensive approach required.
References: Clinical Chemistry Guidelines 2023, Indian Journal of Endocrinology 2024, Metabolic Syndrome Studies 2025.
